NCT Number: NCT05011188
Phase: Phase 1|Phase 2
Trial Summary: This is a Phase 1b/2 study evaluating FOR46 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) after prior progression on abi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Rahul Aggarwal
Acronym:
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives